CSME BCVA. OCT Bevacizumab CMT CMT BCVA. BCVA LogMAR. p CMT NPDR PDR PDR. Bevacizumab PDR FDA. Ranibizumab. Bevacizumab.

Size: px

Start display at page:

Download "CSME BCVA. OCT Bevacizumab CMT CMT BCVA. BCVA LogMAR. p CMT NPDR PDR PDR. Bevacizumab PDR FDA. Ranibizumab. Bevacizumab."

Owen Jayson Blankenship
5 years ago
Views:

1 Bevacizumab FDA mg Ranibizumab - Bevacizumab NPDR PDR PDR PDR CSME FAZFA BCVA CMT OCT Bevacizumab BCVA CMT BCVA LogMAR p CMT p

2 CSME CRVO CSME BRVO CRVOBRVO (fovea avascular zone) FAZ FAZ OCT 250mg mg 27gauge IOP BCVA BCVA VA OCT BCVA Log MAR decimal BCVA - clinical trial tertiary BCVA VA IOP CSME (clinically significant macular edema) -

3 ± ± < ( ) p< OCT ± ± < ± ± < Log MAR OCT ±SD OCT ±SD Pvalue BCVA Log MAR Log MAR p VA ± ± < ± ± ± ± < Log MAR SD± Log MAR SD± LogMA R Pvalue CSME p< SPSS-9 CSME CSME NPDR I II > y > y OD OS I II >y > y I II > y > y OD OS mild NPDR moderate NPDR Severe NPDR very sever NPDR PDR OD OS NPDR CSME OCT CSME CSME OCT OCT

4 - Arevalo Avastin. BCVA LogMAR CMT Sinha Kumar. mg Bevacizumab Log MAR BCVA CMT BCVA Roh mg Bevacizumab BCVA CMT EDTRS CMT BCVA Velez Montoya CMT DME Bevacizumab CMT BCVA Bevacizumab Chung Bevacizamab Bevacizumab FA Bevacizumab FAZ FAZ Capillary non-perfusion CSME CSME CSME II I II CSME II II PDR NPDR CSME PDR CSME NPDR NPDR Severe NPDR NPDR CSME mild NPDR CSME NPDR LogMAR VA Capillary non- perfusion Cone Rod VA

5 AntiVEGF CSME VA VEGF VA -. Bevacizumab References DME OCT VA VA Log MAR BCVA BCVA BCVA DME Bevacizumab VA BCVA BCVA VEGF 1. Regillo C, Chang T, Johnson M,etal. American academy of ophthalmology: Retina and vitreous united state of America, LEO, : Schwartz SG, Flynn HW Jr. Pharmacotherapies for diabetic retinopathy: Present and future. Exp Diabetes Res 2007; 2007: Chibber R, Cibber S, Kohner EM. 21 th century treatment of diabetic retinopathy. Exp Rev Endocrine Metabol 2007; 2(5): Smit DP, Meyer D. Intravitreal bevacizumab: An analysis of the evidence. Clin Ophthalmol 2007; 1(3): Fraser-Bell S, Kaines A, Hykin PG. Update on treatments for diabetic macular edema. Curr Opin Ophthalmol 2008; 19(3): Conway MD, OIK RJ. Diabetic maculopathies: Diagnosis and treatment. Ophthalmol Clin N Am 1993; 6: Patz A, Smith RE. The ETDRS and diabetes Ophthalmology 1991; 98(5 suppl): OIK RJ. Diabetic retinopathy. In: Yannuzzi LA. Laser photocoagulation of the macula. Philadelphia: JB Lippincott; 1989: Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. primary intravitral Bevacizumab (Av astin) diabetic macular edema: Results From the panamerican collaborative Retina study group at 6 month follow up. Ophthalmology 2007; 114(4): Kumar A, Sinha S. intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Indian J Ophthalmol 2007; 55(6): Roh MI, Byeon SH, Kwon OW. Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema. Retina 2008; 28(9): Velez-Montoya R, Fromow-Guerra J, Burgos O, et al. The effect of unilateral intravitreal bevacizumab (Avastin), in the treatment of diffuse bilateral diabetic macular edema: A pilot study. Retina 2009; 29(1): Chung EJ, Roh MI, Kwon OW, etal. Effect of intravitreal bevacizumab therapy for diabetic macular edema. Retina 2008; 28(7):

6 Comparison Effect of Interavitrealbevacizumab (Avastin) in Visual Acuity of Ischemic and Non Ischemic Diabetic Macular Edema Farzaneh Ghasemzadeh, 1 Reza Jafari 2 Received: 20/Dec/2011 Accepted: 30/Dec/2011 Background:To evaluate effect of ischemia in visual outcome after intravitrel injection of Avastin (Bevacizumab) for diabetic macular edema prospective interventional ( clinlical trial) study tertiary eye centre, Alzahra, zahedan, Iran. Materials and Method: patient with clinically significant Macular edema (CSME) undergone fluorsceine angiography (FA) Patient with fovea avascular zone(faz) larger than 100micrometer were defined to have ischemic macular edema.patientdevided in 2 groupes: ischemic and non Ischemic. Best corrected visual acuity (BCVA) and central macular thickness (CMT) measured in all eyes with optical coherence tomography (OCT) at baseline. then 3 times Injection of Avastin (Bevacizumab) intravitreally was done monthly. 1 month after third injection BCVA and CMT measured again: then data Compared before and after injection in 2 groupes. Results: 87 eye (66 patie nts ), 23 eye (26.4%) ischemic and 64 eyes (73.6%) nonischemic group. BCVA in nonischemic group improves from base line Log MAR to (pvalue< 0.001) and BCVA in ischemic group had no significant changes to (pvalue = 0.906). CMT improved in ischemic group from to (pvalue< 0.001) and in non ischemic group from to (pvalue< 0.001). Conclusion: despite significant effect of intravitreal injection of bevacizumab in reducing of CMT in both ischemic and nonischemicgroupes. BCVA improved significantly in non ischemic group and no change in ischemic group. Keywords:Avastin, ischemic macular edema, nonischemic macular edema,diabetes

Is OCT-A Needed As An Investigative Tool During The Management Of Diabetic Macular Edema

Is OCT-A Needed As An Investigative Tool During The Management Of Diabetic Macular Edema Ayman M Khattab MD, FRCS Professor of Ophthalmology Cairo University Diabetic Macular Edema (DME) Diabetic macular